Oxonic Acid

The onset of hyperuricemia and gout is directly related to the disorder of uric acid metabolism in the body. In clinical intervention, it is often necessary to simulate the characteristics of human uric acid metabolism by inhibiting uricase activity, so as to provide reliable animal models for drug screening and pathological research. Oteracil acid belongs to uricase inhibitor drugs. It reversibly binds to the active site of uricase, blocks the conversion process of uric acid to allantoin, increases the uric acid level in experimental animals, and stably simulates the pathological state of hyperuricemia. It is one of the most widely used modeling reagents in pharmacological research and efficacy evaluation related to gout and hyperuricemia, and can also be used as a pharmaceutical synthesis intermediate for the preparation of related gout therapeutic drugs.

At present, the global research market for hyperuricemia-related diseases continues to expand, driving the annual growth rate of the scientific research application demand for oteracil acid to remain at around 11%. The global supply of oteracil acid is mainly dominated by European and American special reagent manufacturers and Chinese fine chemical manufacturers, among which China's production capacity accounts for about 62% of the global total production capacity, and most products are supplied to global scientific research institutions, CRO enterprises and pharmaceutical R&D companies. The compound growth rate of domestic biomedical R&D investment in the past three years has exceeded 18%, among which the annual growth rate of the number of gout new drug R&D pipelines has reached 22%, directly driving the continuous rise of the market demand for oteracil acid.

There is no exclusive original research drug for oteracil acid. The current mainstream medicinal-grade oteracil acid in the world was first mass-produced by Nippon Kayaku Co., Ltd. under the trade name Oxonic Acid. At present, all relevant production process patents have expired. There are 2 domestic enterprises whose oteracil acid API has obtained the CDE API registration number, both in status A, which can be used in association with domestic preparation declarations. At present, no preparation with oteracil acid as the active ingredient has been approved for marketing in China, and its application is mainly focused on scientific research modeling and synthetic intermediates. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of oteracil acid impurity reference standards, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. They meet the compliance requirements of multiple regulations including the Chinese Pharmacopoeia and FDA, and can fully meet various needs in the R&D stage such as qualitative and quantitative analysis of impurities, establishment of quality standards and preparation of application documents.